<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HDC4FD0803E394150AB02200256EB2982" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 3964 IH: Opioid Addiction Prevention Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-10-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3964</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20171005">October 5, 2017</action-date><action-desc><sponsor name-id="R000582">Mr. Roe of Tennessee</sponsor> (for himself, <cosponsor name-id="K000382">Ms. Kuster of New Hampshire</cosponsor>, <cosponsor name-id="M001193">Mr. MacArthur</cosponsor>, <cosponsor name-id="R000600">Mrs. Radewagen</cosponsor>, and <cosponsor name-id="G000582">Miss González-Colón of Puerto Rico</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act to establish additional registration requirements for
			 prescribers of opioids, and for other purposes.</official-title></form>
	<legis-body id="H9282BD8E57E746B0B1EC367C3CAB8EEE" style="OLC">
 <section id="HC239EC05B4D2407DB40D2313050689B3" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Opioid Addiction Prevention Act of 2017</short-title></quote>.</text> </section><section id="H16A2C62F3FA34952B1ED94D1AB8BAF1C"><enum>2.</enum><header>Registration requirements for prescribers</header><text display-inline="no-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block id="HCC0EC159F78344FDB06A722F4977A5E2" style="OLC">
				<subsection id="H23DB12114F0A494A929FAA79678E9BBF"><enum>(k)</enum>
 <paragraph commented="no" display-inline="yes-display-inline" id="H22A3C9FDCA0C4328BAB2ECA25140196F"><enum>(1)</enum><text>The Attorney General shall not register, or renew the registration of, a practitioner under subsection (f) who is licensed under State law to prescribe controlled substances in schedule II, III, or IV, unless the practitioner submits to the Attorney General, for each such registration or renewal request, a certification that the practitioner, during the applicable registration period, will not prescribe, for the initial treatment of acute pain, any schedule II, III, or IV opioid, other than an opioid prescription described in paragraph (3)—</text>
 <subparagraph id="H53A0347B33BC407BA3D08D01512D4E76" indent="up1"><enum>(A)</enum><text>without firstly or concomitantly prescribing one or more non-opioid analgesics, if there are no contraindications to such analgesics;</text>
 </subparagraph><subparagraph id="HD2DF6349ABFD4B8C97567A6D910E429B" indent="up1"><enum>(B)</enum><text>without clearly stating on the prescription the diagnosis for which the opioid is prescribed;</text> </subparagraph><subparagraph id="HF8DF8774FBCA4E4F9B7A8DBFC1DD42BF" indent="up1"><enum>(C)</enum><text>unless the prescribed opioid dose is the lowest effective dose;</text>
 </subparagraph><subparagraph id="HDE874A30F4174D4087E523EA73F8C48A" indent="up1"><enum>(D)</enum><text>an extended release or long acting formulation of the opioid; and</text> </subparagraph><subparagraph id="HAB2D0357A2B5469C8251E4B574E0F046" indent="up1"><enum>(E)</enum><text>in an amount in excess of the lesser of—</text>
 <clause id="H535B42E511714904902865796CF2E743"><enum>(i)</enum><text>a 10-day supply (for which no refill is available); or</text> </clause><clause id="H9F2E5195E1D94D0797C83D7B562ED59F"><enum>(ii)</enum><text>an opioid prescription limit established under State law.</text>
 </clause></subparagraph></paragraph><paragraph id="H4E7D4E0B814C4B46B27640DD83441C44" indent="up1"><enum>(2)</enum><text>In this subsection, the term <term>acute pain</term>—</text> <subparagraph id="H7C26A4E0E4B54A3C9A21AC4542AE9F70"><enum>(A)</enum><text>means pain with abrupt onset and caused by a discrete injury, surgical procedure, or other illness of limited duration; and</text>
 </subparagraph><subparagraph id="H76B08ABD0DAE43C590191F2FF44F88BB"><enum>(B)</enum><text>does not include—</text> <clause id="H1CF9B3B81E72455F9898F44E95D14AD8"><enum>(i)</enum><text>chronic pain;</text>
 </clause><clause id="H9BA7DC5323E84D39A7F84B77C6C29460"><enum>(ii)</enum><text>pain being treated as part of cancer care;</text> </clause><clause id="H3B787E421865497BB896FB60FC35EC6A"><enum>(iii)</enum><text>hospice or other end-of-life care; or</text>
 </clause><clause id="HEAEA4E9226764CBD8E972FCEE9C33620"><enum>(iv)</enum><text>pain being treated as part of palliative care.</text> </clause></subparagraph></paragraph><paragraph id="HE39D831F1E6A48CDA00CEAA0B273B33D" indent="up1"><enum>(3)</enum><text>An opioid prescription described in this paragraph is a prescription—</text>
 <subparagraph id="H29DB0CC939B14C278FFEDBE5CA0245AC"><enum>(A)</enum><text>for a schedule II, III, or IV opioid drug approved by the Food and Drug Administration for an indication for the treatment of addiction; and</text>
 </subparagraph><subparagraph id="H6AC41B16C5114555AFB8B1FD7F330FEF"><enum>(B)</enum><text>that is for the treatment of addiction.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </section></legis-body></bill> 

